Can Sarepta’s Duchenne gene therapy still deliver on its promise?

For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

By Kelly Bilodeau • Nov. 14, 2023

Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

By Kelly Bilodeau • Nov. 13, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

What if a CRISPR cure isn’t such an easy choice?

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023

23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

By Alexandra Pecci • Nov. 7, 2023

PharmaVoice 100s: Entrepreneurs

From biotech startups to a services agency, these entrepreneurs are hedging their bets to offer innovative approaches in patient care.

By Meagan Parrish • Nov. 3, 2023

How Big Pharma keeps the oncology engines hot with a host of strategies

From Merck and J&J to AbbVie and Eisai, the oncology field has stayed consistently devoted to churning out important therapies.

By Michael Gibney • Nov. 2, 2023

Tools like ChatGPT can personalize clinical trials tech — if companies avoid the pitfalls

From hallucinations to data privacy, pharma looks to iron out the kinks of generative AI.

By Kelly Bilodeau • Nov. 1, 2023

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

Roivant Sciences CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities.

By Michael Gibney • Oct. 31, 2023

Red Jacket: Dr. Mark Goldberg, a clinical innovator

Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.

By Alexandra Pecci • Oct. 27, 2023

Red Jacket: Ken Getz, a champion of clinical trials

Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.

By Alexandra Pecci • Oct. 27, 2023

The 2023 Red Jacket honorees

This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

By Meagan Parrish • Oct. 27, 2023

Red Jacket: Helen Sabzevari, an immunotherapy pioneer

Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

By Meagan Parrish • Oct. 27, 2023

Cidara’s J&J-partnered immunotherapy could target flu and cancer

On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

By Alexandra Pecci • Oct. 26, 2023

Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

By Kelly Bilodeau • Oct. 25, 2023

An ‘inverse vaccine’ takes aim at autoimmune diseases

Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

By Kelly Bilodeau • Oct. 23, 2023

PharmaVoice 100s: Clinical trial gurus

Industry leaders adopting cutting-edge technologies and strategies to change the paradigm of clinical research.

By Meagan Parrish • Oct. 19, 2023

From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

By Kelly Bilodeau • Oct. 17, 2023

Has the science of anti-aging caught up with the dream of a longer life?

Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

By Kelly Bilodeau • Oct. 16, 2023

Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

By Michael Gibney • Oct. 12, 2023

A decade later, biotech’s CRISPR revolution is still going strong

Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023

To close the pediatric innovation gap, this biotech has to think differently

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

By Alexandra Pecci • Oct. 11, 2023

5 minutes with — IDEA Pharma’s Mike Rea

The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

By Meagan Parrish • Oct. 11, 2023

Google bets on AI in the life sciences as ‘technology for a purpose’

A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

By Alexandra Pecci • Oct. 10, 2023

Research in space yields clues about boosting bone health on Earth

A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.

By Kelly Bilodeau • Oct. 10, 2023

A biotech ‘tuning’ the genome for a potentially safer gene therapy

Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

By Kelly Bilodeau • Oct. 9, 2023